C-((R)-1-isopropylpiperidin-3-yl)methylamine | 1336910-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: C-((R)-1-isopropylpiperidin-3-yl)methylamine
• 英文别名: [(3R)-1-propan-2-ylpiperidin-3-yl]methanamine
• CAS: 1336910-15-6
• 化学式: C₉H₂₀N₂
• mdl: MFCD07186370
• 分子量: 156.271
• InChiKey: FGNRRDAUWGLVRV-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  C-((R)-1-isopropylpiperidin-3-yl)methylamine 在 1-羟基苯并三唑 、 原乙酸三乙酯 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 (S)-6-chloro-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,4-d]pyrimidin-4(3H)-one
  参考文献：
  名称：

  Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity

  摘要：

  Substituted azaquinazolinones were identified as antagonists of the GHSr-1A receptor for the treatment of type II diabetes and obesity. Optimisation for potency and LogD lead to the identification of orally bioavailable, potent antagonists with improved selectivity over hERG. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.078

文献信息

• Heterocyclic inhibitors of PCSK9
  申请人：CARDIO THERAPEUTICS PTY LTD

  公开号：US11091466B2

  公开（公告）日：2021-08-17

  This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include comprising of Formula (I): (I) wherein A, D and Q are described herein.

  本申请涉及可作为 PCSK9 抑制剂或以其他方式调节 PCSK9 活性的化合物，或其药学上可接受的盐、溶液剂、原药或多晶型物，还涉及包含此类化合物的组合物和制剂，以及使用和制造此类化合物的方法。化合物包括式（I）：(I) 其中 A、D 和 Q 如本文所述。
• MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS
  申请人：Fundación Centro Nacional de Investigaciones Oncológicas Carlos III

  公开号：EP2710018B1

  公开（公告）日：2021-12-29
• HETEROCYCLIC INHIBITORS OF PCSK9
  申请人：CARDIO THERAPEUTICS PTY LTD

  公开号：US20200207743A1

  公开（公告）日：2020-07-02

  This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include comprising of Formula (I): (I) wherein A, D and Q are described herein.
• Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity
  作者：Patrick Hanrahan、James Bell、Gillian Bottomley、Stuart Bradley、Phillip Clarke、Eleanor Curtis、Susan Davis、Graham Dawson、James Horswill、John Keily、Gary Moore、Chrystelle Rasamison、Jason Bloxham

  DOI：10.1016/j.bmcl.2012.01.078

  日期：2012.3

  Substituted azaquinazolinones were identified as antagonists of the GHSr-1A receptor for the treatment of type II diabetes and obesity. Optimisation for potency and LogD lead to the identification of orally bioavailable, potent antagonists with improved selectivity over hERG. (C) 2012 Elsevier Ltd. All rights reserved.